Using the well-described human NSCLC cell line PC9, which harbors an oncogenic EGFR exon 19 deletion, they observed that a small fraction constituting ~0.3% of the original population survived treatment with a lethal dose of the EGFR inhibitor erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.